ABSTRACT
Descrevemos um caso de perda visual irreversível bilateral em uma paciente de 64 anos após uso prolongado de paclitaxel. Ao exame oftalmológico paciente apresentou acuidade visual (AV) de 20/400 em ambos os olhos (AO) na primeira consulta. À tomografia de coerência óptica (TCO) evidenciou espessamento macular AO. Após seis meses da suspensão do paclitaxel, a paciente apresentava melhora discreta da AV atingindo 20/200 com correção em AO, além da TCO demonstrando resolução do espessamento retiniano.
We describe a case of bilateral irreversible visual loss of a 64 year-old patient after prolonged use of paclitaxel. Patient presented best corrected visual acuity of 20/400 in both eyes at first visit and optical coherence tomography showed increased macular in both eyes.After six months of the interruption of -paclitaxel therapy, the patient showed slight improvement of visual acuity reaching 20/200 in both eyes, while OCT demonstrated resolution of macular edema.
Subject(s)
Humans , Female , Middle Aged , Visual Acuity , Antineoplastic Agents, Phytogenic/adverse effects , Antineoplastic Agents, Phytogenic/toxicity , Macular Edema/chemically induced , Paclitaxel/adverse effects , Paclitaxel/toxicityABSTRACT
Objective To explore the inhibitory effects of lobaplatin and cisplatin and their regulation of apoptosis-related genes in ovarian cancer cells in nude mice.Methods SKOV3 cells were implanted into nude mice.In monotherapy treatment study,the nude mice bearing human SKOV3 cells were randomly divided into control,lobaplatin,and cisplatin groups,with 7 mice in each group.The mice in each group were received corresponding treatment.The volume of tumor and the weight of nude mice were measured three times per week,respectively.Tumor inhibitory rate was calculated.The protein expressions of bax and bcl-2 were detected by flow cytometry.Results The growth inhibitory rate was 47.2％ in lobaplatin group and 42.8％ in cisplatin group,without significant difference between two groups (P ＞ 0.05).The expression of bcl-2 was decreased but the bax was increased in lobaplatin and ciaplatin groups compared to the control group.Conclusions Lobaplatin can significantly inhibit the growth of ovarian cancer cells,induce apoptosis by down-regulation of bcl-2 and up-regulation of bax.
ABSTRACT
Objective To investigate the potentiality of specific miRNA level in blood plasma of ovarian cancer patients as a molecular marker to predict sensitivity and response to platinum-based chemotherapy .Methods Quantitative polymerase chain reac-tion ( Q-PCR) was used to check the changing of miRNA level in blood plasma before and after chemotherapy , and explored the rela-tivity between variation and chemotherapy response and clinic outcome .Results Among preliminary screened 11 miRNAs, only 5 miRNAs were able to be detected in peripheral blood .There existed variations in 3 miRNAs ( miR-22, miR-106a, miR-142).Further detection of the changing of miRNA level in blood plasma before and after therapy , miR-22 was found significantly up-regulated in blood plasma that was underwent platinum-based chemotherapy .Meanwhile, ovarian cancer patients with high miR-22 level were most-ly sensitive to platinum-based therapy.Otherwise, miR-22 was positive relative to the clinic prognosis of patients with ovarian cancer . Conclusions miR-22, miR-106a, and miR-142 might participate in the generation and development of ovarian cancer .miR-22 in pe-ripheral blood was probably identified as a novel molecular marker of prediction of the sensitivity to platinum in ovarian cancer patients .
ABSTRACT
Objective: To assess if the genotype of the glutathione S-transferase M1 (GSTM1) enzyme and its GSTM1 null polymorphism can influence the response to chemotherapeutic treatment of advanced ovarian cancer. Methods: Case-control study of 112 patients with advanced ovarian cancer submitted to chemotherapy during the period from January 1995 to December 2005. The tissue to study the GSTM1 genotype and its deletion came from surgical staging to treat ovarian cancer. The PCR product generates two distinct genotypes, characterized as positive and null. The response to chemotherapy was evaluated using the World Health Organization (WHO) criteria.Patients were classified as having: a) no response, b) a response. Results: The presence of GSTM1 or its GSTM1 null polymorphism did not influence the preoperative chemotherapy response. Among the patients who did respond, 88.9% presented with positive GSTM1 and 11.1% with null GSTM1. Among the patients that did not respond, 85.71% presented with positive GSTM1 and 14.29% with null GSTM1 (p = 0.825). GSTM1 and its GSTM1 null polymorphism had no influence on the postoperative response to chemotherapy. Among the patients who did respond, 80.65% presented with positive GSTM1 and 19.35% with null GSTM1. Among the patients who did not respond, 87.50% presented with positive GSTM1 and 12.5% with the null polymorphism (p = 0.553). Conclusion: No difference was observed in the response to treatment with chemotherapy in patients with advanced ovarian cancer, as to the GSTM1 genotype compared to its GSTM1 null polymorphism.
Objetivo: Avaliar se o genótipo da enzima glutationa S-transferase M1 (GSTM1) e seu polimorfismo GSTM1 nulo podem influenciar na resposta ao tratamento quimioterápico do câncer avançado de ovário. Métodos: Estudo caso-controle de 112 pacientes portadoras de câncer avançado de ovário, submetidas a tratamento por quimioterapia no período de Janeiro de 1995 a Dezembro de 2005. O tecido para estudo do genótipo da GSTM1 e sua deleção foram provenientes do estadiamento cirúrgico para tratamento do câncer de ovário. O produto do PCR gera dois genótipos distintos, sendo caracterizado como positivo e nulo. A resposta à quimioterapia foi avaliada usando os critérios da Organização Mundial da Saúde. As pacientes foram classificadas em: a) sem resposta, b) com resposta. Resultados: A presença da GSTM1 ou seu polimorfismo GSTM1 nulo não influenciou na resposta à quimioterapia pré-operatória. Dentre as pacientes que responderam 88,9% apresentavam GSTM1 e 11,1% GSTM1 nulo. Dentre as pacientes que não responderam 85,71% apresentavam GSTM1 e 14,29% GSTM1 nulo (p = 0, 825). A GSTM1 e seu polimorfismo GSTM1 nulo não tiveram influência na resposta à quimioterapia pós-operatória. Dentre as pacientes que responderam 80,65% apresentavam GSTM1 e 19,35% nulo. Dentre as pacientes que não responderam, 87,50% apresentavam GSTM1 e 12,5% nulo ( p = 0,553). Conclusão: Não foi observada diferença na resposta ao tratamento com quimioterapia em pacientes com câncer avançado de ovário, em relação ao genótipo GSTM1 comparado ao seu polimorfismo GSTM1 nulo.